BiomX (PHGE)
Market Price (4/20/2026): $1.82 | Market Cap: $3.0 MilSector: Health Care | Industry: Biotechnology
BiomX (PHGE)
Market Price (4/20/2026): $1.82Market Cap: $3.0 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -136%, 3Y Excs Rtn is -170% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -32 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1233% High stock price volatilityVol 12M is 1911% Key risksPHGE key risks include [1] a critical cash shortage highlighted by a "going concern" qualification from its auditors, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -136%, 3Y Excs Rtn is -170% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -32 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -1233% |
| High stock price volatilityVol 12M is 1911% |
| Key risksPHGE key risks include [1] a critical cash shortage highlighted by a "going concern" qualification from its auditors, Show more. |
Qualitative Assessment
AI Analysis | Feedback
BiomX (PHGE) stock has remained largely at the same level since 12/31/2025 because of the following key factors:
1. Strategic pivot into the defense and security markets has generated new opportunities. BiomX announced an option agreement to acquire control of DFSL, a developer of laser radar-based detection systems, and separately acquired Zorronet, an autonomous AI command-and-control platform, signaling a strategic shift towards these new markets in April 2026. This was further solidified by the appointment of a former Mossad Deputy to its Advisory Board on March 31, 2026, to guide strategic decisions in the defense sector, and the launch of a new security subsidiary in Israel with an initial investment of over $3 million in its operations in March 2026.
2. Positive clinical development updates for its phage therapy pipeline continue to support investor confidence. The BX211 program for diabetic foot osteomyelitis (DFO) has demonstrated positive Phase 2 results with over 40% reduction in ulcer size compared to placebo. This program is significantly bolstered by approximately $40 million in non-dilutive funding from the U.S. Defense Health Agency (DHA). Additionally, the BX004 Phase 2b trial for cystic fibrosis is on track to report topline results in Q2 2026, following positive FDA feedback outlining potential development pathways.
Show more
1. Strategic pivot into the defense and security markets has generated new opportunities. BiomX announced an option agreement to acquire control of DFSL, a developer of laser radar-based detection systems, and separately acquired Zorronet, an autonomous AI command-and-control platform, signaling a strategic shift towards these new markets in April 2026. This was further solidified by the appointment of a former Mossad Deputy to its Advisory Board on March 31, 2026, to guide strategic decisions in the defense sector, and the launch of a new security subsidiary in Israel with an initial investment of over $3 million in its operations in March 2026.
2. Positive clinical development updates for its phage therapy pipeline continue to support investor confidence. The BX211 program for diabetic foot osteomyelitis (DFO) has demonstrated positive Phase 2 results with over 40% reduction in ulcer size compared to placebo. This program is significantly bolstered by approximately $40 million in non-dilutive funding from the U.S. Defense Health Agency (DHA). Additionally, the BX004 Phase 2b trial for cystic fibrosis is on track to report topline results in Q2 2026, following positive FDA feedback outlining potential development pathways.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -1.6% change in PHGE stock from 12/31/2025 to 4/19/2026 was primarily driven by a 0.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 12312025 | 4192026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.87 | 1.84 | -1.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 2 | 0.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
12/31/2025 to 4/19/2026| Return | Correlation | |
|---|---|---|
| PHGE | -1.6% | |
| Market (SPY) | -5.4% | 6.2% |
| Sector (XLV) | -3.9% | -25.6% |
Fundamental Drivers
The -81.6% change in PHGE stock from 9/30/2025 to 4/19/2026 was primarily driven by a -0.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 9302025 | 4192026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.97 | 1.84 | -81.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 2 | 2 | -0.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
9/30/2025 to 4/19/2026| Return | Correlation | |
|---|---|---|
| PHGE | -81.6% | |
| Market (SPY) | -2.9% | 12.2% |
| Sector (XLV) | 7.4% | 19.2% |
Fundamental Drivers
The -82.6% change in PHGE stock from 3/31/2025 to 4/19/2026 was primarily driven by a -42.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312025 | 4192026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.56 | 1.84 | -82.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 1 | 2 | -42.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2025 to 4/19/2026| Return | Correlation | |
|---|---|---|
| PHGE | -82.6% | |
| Market (SPY) | 16.3% | 5.7% |
| Sector (XLV) | 3.3% | 12.0% |
Fundamental Drivers
The -96.8% change in PHGE stock from 3/31/2023 to 4/19/2026 was primarily driven by a -90.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 3312023 | 4192026 | Change |
|---|---|---|---|
| Stock Price ($) | 57.95 | 1.84 | -96.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 2 | -90.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
3/31/2023 to 4/19/2026| Return | Correlation | |
|---|---|---|
| PHGE | -96.8% | |
| Market (SPY) | 63.3% | 4.5% |
| Sector (XLV) | 20.3% | 9.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| PHGE Return | -75% | -88% | 50% | -74% | -87% | 5% | -100% |
| Peers Return | 17% | -63% | 4% | -59% | 50% | 24% | -66% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 3% | 87% |
Monthly Win Rates [3] | |||||||
| PHGE Win Rate | 17% | 33% | 42% | 25% | 17% | 25% | |
| Peers Win Rate | 38% | 33% | 42% | 33% | 52% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| PHGE Max Drawdown | -77% | -92% | -1% | -82% | -98% | 0% | |
| Peers Max Drawdown | -31% | -73% | -48% | -64% | -50% | -25% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ARMP, MCRB, SYBX, NTLA, EDIT.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/17/2026 (YTD)
How Low Can It Go
| Event | PHGE | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -98.4% | -25.4% |
| % Gain to Breakeven | 6300.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -54.9% | -33.9% |
| % Gain to Breakeven | 121.7% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
Compare to ARMP, MCRB, SYBX, NTLA, EDIT
In The Past
BiomX's stock fell -98.4% during the 2022 Inflation Shock from a high on 3/2/2021. A -98.4% loss requires a 6300.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About BiomX (PHGE)
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
AI Analysis | Feedback
BiomX is like Moderna, but instead of mRNA vaccines, they use viruses (phages) to precisely kill harmful bacteria.
BiomX is like Crispr Therapeutics, but instead of editing human genes, they use viruses to precisely eliminate specific harmful bacteria.
AI Analysis | Feedback
- BX004: A phage therapy for cystic fibrosis patients with chronic Pseudomonas aeruginosa respiratory infections.
- BX005: A topical phage cocktail targeting Staphylococcus aureus for atopic dermatitis.
- BX003: An orally administered phage cocktail for inflammatory bowel diseases and primary sclerosing cholangitis.
- Colorectal Cancer Program: An engineered phage therapy targeting Fusobacterium nucleatum bacteria within the tumor microenvironment for colorectal cancer.
AI Analysis | Feedback
BiomX Inc. (PHGE) is a clinical-stage microbiome company developing therapeutic products that are currently in various phases of clinical trials. As such, it does not yet have commercially approved products or major customers that purchase its therapies or services. Its products are investigational drugs targeting specific patient populations (e.g., CF patients, IBD and PSC patients, individuals with atopic dermatitis, or colorectal cancer patients), but these products are not yet available for sale.
AI Analysis | Feedback
null
AI Analysis | Feedback
Michael Oster, Chief Executive Officer
Michael Oster brings over 25 years of experience in corporate finance, mergers and acquisitions (M&A), and complex international transactions, having held senior leadership roles in both public and private companies. He currently serves as Chief Executive Officer and a board member of Saffron Tech Ltd., an agritech company, and as a board member of BladeRanger Ltd., a publicly traded Israeli innovator in advanced drone payload systems. Earlier in his career, he was the Senior Vice President of Mergers and Acquisitions at Alon USA Energy, Inc., where he led numerous strategic transactions.
David Rokach, Chief Financial Officer
David Rokach possesses over two decades of experience in finance, investment management, and corporate leadership. He is responsible for BiomX’s financial strategy, capital markets activities, accounting, and investor relations. Since 2024, he has been a member of the board of directors of T3 Defense Inc. Previously, he held Chief Executive Officer positions at Newcom Finance and Granit Investment Company, and he has provided strategic and financial advisory services to corporations and hedge funds.
AI Analysis | Feedback
The key risks to BiomX (PHGE) are primarily centered around its financial viability and the success of its clinical development pipeline.
- Clinical Trial Failures and Regulatory Hurdles: A significant risk for BiomX stems from the inherent uncertainties of pharmaceutical research and development and the stringent regulatory approval process. In a major setback, BiomX announced the discontinuation of its Phase 2b clinical trial for nebulized phage therapy BX004, intended for cystic fibrosis patients with chronic Pseudomonas aeruginosa infections, in December 2025. This decision followed an internal analysis and recommendations from an independent Data Monitoring Committee due to unexpectedly high rates of adverse events. Prior to this, the U.S. portion of the BX004 Phase 2b study was already under an FDA clinical hold, albeit related to a third-party nebulizer and not the drug product itself, causing delays. The inability to successfully advance its primary drug candidates through clinical trials and obtain regulatory approval poses a critical threat to the company's future.
- Going Concern Risk and Insufficient Funding: BiomX faces substantial doubt about its ability to continue as a going concern due to severe liquidity pressure. As of September 30, 2025, the company reported a cash balance of $8.1 million, which was estimated to be sufficient to fund operations only into the first quarter of 2026. This necessitates securing additional financing or entering into partnerships, which could lead to significant shareholder dilution. The financial distress is so acute that in December 2025, BiomX initiated insolvency proceedings for its Israeli subsidiary, BiomX Ltd., which previously housed core operations and contributed to accumulated debts of approximately NIS 11 million (around $3.4 million).
- Lack of Revenue Generation: As a clinical-stage biotechnology company, BiomX has no approved products on the market and has not generated any revenue from product sales. The company operates at a net loss, with significant investment in research and development. This pre-revenue status means that BiomX is entirely reliant on external funding to advance its pipeline, making it highly vulnerable to the success of its clinical programs and its ability to raise capital.
AI Analysis | Feedback
nullAI Analysis | Feedback
BiomX (PHGE) targets several significant addressable markets with its phage technology products:
- BX004 for Cystic Fibrosis (CF) with Pseudomonas aeruginosa respiratory infections: The global cystic fibrosis therapeutics market was valued at $12.9 billion in 2024 and is projected to reach $32.3 billion by 2034. The global Pseudomonas aeruginosa treatment market was valued at $5.84 billion in 2024 and is projected to reach $11.81 billion by 2032. Specifically for BX004, the U.S. market in CF patients with chronic lung infections caused by Pseudomonas aeruginosa is estimated to be over $1 billion.
- BX005 for Atopic Dermatitis targeting Staphylococcus aureus: The global atopic dermatitis drugs market was valued at approximately $12.1 billion in 2024 and is estimated to grow to $31 billion by 2034. Another source indicates the global atopic dermatitis treatment market was valued at $17.05 billion in 2024 and is expected to reach $32.04 billion by 2032.
- BX003 for Inflammatory Bowel Diseases (IBD) and Primary Sclerosing Cholangitis (PSC): The global inflammatory bowel disease treatment market is expected to be valued at approximately $25.5 billion in 2025 and is estimated to reach $36.4 billion by 2032. The global primary sclerosing cholangitis (PSC) market size was valued at approximately $800 million in 2023 and is projected to grow to $1.2 billion by 2032.
- Colorectal Cancer (CRC) program targeting Fusobacterium nucleatum: The global colorectal cancer therapeutics market size was valued at $12.79 billion in 2024 and is expected to reach approximately $19.95 billion by 2034.
AI Analysis | Feedback
BiomX Inc. (PHGE), a clinical-stage microbiome company, is not expected to generate significant commercial revenue within the immediate 2-3 year timeframe (2026-2028), as analysts currently forecast $0 revenue for 2026 and 2027, with some projections of approximately $11.2 million in 2028. Therefore, the primary drivers of future revenue growth for BiomX are centered on the successful advancement of its pipeline through clinical development and regulatory milestones, which would pave the way for eventual product commercialization. Here are the expected drivers of future revenue growth for BiomX over the next 2-3 years: * Advancement of Lead Clinical Programs Through Key Milestones: The successful progression of BiomX's lead product candidates, BX004 and BX011/BX211, through significant clinical trial readouts and positive regulatory interactions, is paramount for future revenue growth. This includes the anticipated topline results for the Phase 2b clinical trial of BX004, a phage therapy for cystic fibrosis patients with *Pseudomonas aeruginosa* respiratory infections, expected in Q1 2026. Additionally, leveraging the positive Phase 2 results for BX211 in diabetic foot osteomyelitis (DFO) and the clear clinical development path for BX011 in diabetic foot infections (DFI) will be crucial for moving these programs closer to market. Favorable feedback from regulatory bodies like the FDA, including supportive guidance for potential Phase 3 development, significantly de-risks these programs and enhances their commercial prospects. * Progression of Earlier-Stage Pipeline Candidates: Expanding and advancing other programs within the pipeline, such as BX003 for inflammatory bowel diseases (IBD) and primary sclerosing cholangitis (PSC), and the colorectal cancer program utilizing engineered phage, will contribute to the company's long-term revenue potential. Even if these programs do not reach commercialization within the next 2-3 years, their successful progression into later-stage clinical development or new indications would broaden BiomX's future market opportunities and increase its overall valuation. * Strategic Partnerships and Non-Dilutive Funding: As a pre-revenue, clinical-stage company, securing strategic collaborations with larger pharmaceutical entities and obtaining additional non-dilutive funding are vital for financing ongoing research and development (R&D) and clinical trials. Such partnerships can provide upfront payments, milestone payments upon achieving specific development or regulatory goals, and potential royalty agreements upon commercialization, thereby directly or indirectly supporting future revenue generation. The significant non-dilutive funding received from the U.S. Defense Health Agency for the BX211 program exemplifies this driver.AI Analysis | Feedback
Share Issuance
- In March 2026, BiomX shareholders approved the authorization to issue shares of Common Stock underlying Series Y convertible preferred stock and accompanying warrants, exceeding 19.99% of the existing Common Stock outstanding prior to the transaction.
- In December 2025, the company finalized agreements for a private investment in public equity (PIPE) that would result in approximately $3.0 million in gross proceeds through the issuance of Series Y Convertible Preferred Stock and warrants.
- In November 2025, BiomX implemented a one-for-nineteen reverse stock split, which reduced the number of outstanding shares from approximately 29 million to around 1.5 million.
Inbound Investments
- In December 2025, BiomX secured approximately $3 million through a private investment in public equity (PIPE) from certain investors.
- In January 2026, Pyu Pyu Capital acquired a 19.99% stake in BiomX, as disclosed in a 13D filing.
- In February 2025, the company raised $12 million in a financing round, which was led by Deerfield Management Company and included significant participation from the Cystic Fibrosis Foundation, along with contributions from Nantahala Capital and other investors.
Capital Expenditures
- For the last 12 months, BiomX's capital expenditures were reported as -$2,000, indicating minimal spending in this area.
- As a clinical-stage biotechnology company, BiomX's investing cash flow is minimal, with its primary focus being on research and development rather than significant capital expenditures.
Trade Ideas
Select ideas related to PHGE.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.19 |
| Mkt Cap | 0.2 |
| Rev LTM | 0 |
| Op Inc LTM | -66 |
| FCF LTM | -27 |
| FCF 3Y Avg | -73 |
| CFO LTM | -27 |
| CFO 3Y Avg | -69 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 16.9% |
| Rev Chg 3Y Avg | 15.4% |
| Rev Chg Q | -19.2% |
| QoQ Delta Rev Chg LTM | -12.6% |
| Op Inc Chg LTM | 23.3% |
| Op Inc Chg 3Y Avg | 2.2% |
| Op Mgn LTM | -448.4% |
| Op Mgn 3Y Avg | -699.4% |
| QoQ Delta Op Mgn LTM | 96.7% |
| CFO/Rev LTM | -495.6% |
| CFO/Rev 3Y Avg | -583.4% |
| FCF/Rev LTM | -497.1% |
| FCF/Rev 3Y Avg | -597.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 0.2 |
| P/S | 17.0 |
| P/Op Inc | -2.8 |
| P/EBIT | -2.2 |
| P/E | -2.3 |
| P/CFO | -2.7 |
| Total Yield | -32.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -112.3% |
| D/E | 0.4 |
| Net D/E | -0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 10.5% |
| 3M Rtn | -5.9% |
| 6M Rtn | -46.3% |
| 12M Rtn | 139.7% |
| 3Y Rtn | -75.6% |
| 1M Excs Rtn | -1.8% |
| 3M Excs Rtn | -4.4% |
| 6M Excs Rtn | -55.4% |
| 12M Excs Rtn | 98.8% |
| 3Y Excs Rtn | -148.6% |
Price Behavior
Price Behavior
| Market Price | $1.84 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 03/13/2019 | |
| Distance from 52W High | -85.1% | |
| 50 Days | 200 Days | |
| DMA Price | $4.67 | $6.54 |
| DMA Trend | down | up |
| Distance from DMA | -60.6% | -71.9% |
| 3M | 1YR | |
| Volatility | 231.7% | 1,922.9% |
| Downside Capture | 3.06 | 4.92 |
| Upside Capture | 703.40 | 532.32 |
| Correlation (SPY) | 4.6% | 8.4% |
PHGE Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.53 | -0.70 | 1.04 | 26.02 | 5.83 | 3.32 |
| Up Beta | 0.59 | -4.71 | -7.43 | 66.50 | 3.62 | 3.00 |
| Down Beta | -3.77 | -2.55 | -1.53 | -0.34 | 0.55 | 0.72 |
| Up Capture | 241% | -26% | 1128% | 13395% | 4996% | 489% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 13 | 28 | 54 | 108 | 331 |
| Down Capture | 30% | 193% | 95% | 308% | 182% | 113% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 14 | 29 | 35 | 72 | 141 | 404 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PHGE | |
|---|---|---|---|---|
| PHGE | -82.7% | 1,911.4% | 0.91 | - |
| Sector ETF (XLV) | 9.6% | 16.0% | 0.39 | 13.1% |
| Equity (SPY) | 21.1% | 12.9% | 1.32 | 8.1% |
| Gold (GLD) | 50.9% | 27.5% | 1.49 | -0.7% |
| Commodities (DBC) | 25.2% | 16.2% | 1.40 | -4.0% |
| Real Estate (VNQ) | 17.5% | 13.7% | 0.93 | 6.4% |
| Bitcoin (BTCUSD) | -7.8% | 42.6% | -0.08 | -2.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PHGE | |
|---|---|---|---|---|
| PHGE | -72.4% | 865.3% | 0.37 | - |
| Sector ETF (XLV) | 6.4% | 14.6% | 0.25 | 7.2% |
| Equity (SPY) | 10.8% | 17.1% | 0.49 | 3.6% |
| Gold (GLD) | 22.6% | 17.8% | 1.04 | 0.6% |
| Commodities (DBC) | 11.6% | 18.8% | 0.51 | -0.8% |
| Real Estate (VNQ) | 4.4% | 18.8% | 0.14 | 2.7% |
| Bitcoin (BTCUSD) | 5.2% | 56.5% | 0.31 | 0.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with PHGE | |
|---|---|---|---|---|
| PHGE | -50.4% | 729.3% | 0.31 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 5.4% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 3.0% |
| Gold (GLD) | 14.3% | 15.9% | 0.75 | 0.7% |
| Commodities (DBC) | 8.5% | 17.6% | 0.40 | -0.5% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.24 | 2.2% |
| Bitcoin (BTCUSD) | 68.4% | 66.9% | 1.07 | 0.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/12/2025 | -1.9% | -96.1% | -68.7% |
| 8/13/2025 | -11.7% | -2.5% | -9.4% |
| 3/25/2025 | -7.2% | -11.8% | -6.2% |
| 11/14/2024 | 3.6% | -29.7% | -12.4% |
| 4/3/2024 | -8.9% | -8.6% | 15.7% |
| 11/14/2023 | -1.2% | -5.2% | -25.0% |
| 8/9/2023 | -9.3% | -10.2% | -7.1% |
| 3/29/2023 | 2.2% | -11.8% | -10.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 4 | 2 | 2 |
| # Negative | 13 | 15 | 15 |
| Median Positive | 6.5% | 15.8% | 10.8% |
| Median Negative | -6.4% | -11.8% | -10.4% |
| Max Positive | 14.4% | 20.9% | 15.7% |
| Max Negative | -16.4% | -96.1% | -68.7% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/13/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/25/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/20/2024 | 10-Q |
| 12/31/2023 | 04/04/2024 | 10-K |
| 09/30/2023 | 11/14/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/29/2023 | 10-K |
| 09/30/2022 | 11/09/2022 | 10-Q |
| 06/30/2022 | 08/10/2022 | 10-Q |
| 03/31/2022 | 05/11/2022 | 10-Q |
| 12/31/2021 | 03/30/2022 | 10-K |
Recent Forward Guidance [BETA]
Latest: Q3 2025 Earnings Reported 11/12/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Cash Runway | |||||||
Prior: Q2 2025 Earnings Reported 8/13/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Cash Runway | Affirmed | Guidance: 1 for Q1 2026 | |||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3132026 | 5.00 | 300,000 | Form | |||
| 2 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3132026 | 5.00 | 370,000 | Form | |||
| 3 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3182026 | 5.00 | 450,000 | Form | |||
| 4 | Yeganeh, Reuven | Pyu Pyu Capital LLC | Sell | 3182026 | 5.00 | 530,000 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.